We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Lipid-Induced Immune Activation Responsible for Increased Myeloma Risk in Gaucher's Disease

By LabMedica International staff writers
Posted on 23 Feb 2016
Analysis of tissue and blood samples from mice and human patients with Gaucher's disease showed that an increased risk for development of myeloma was linked to long-term immune activation by lysophospholipids.

Lysophospholipids are small bioactive lipid molecules characterized by a single carbon chain and a polar head group. More...
Two subgroups can be distinguished: molecules containing the sphingoid base backbone (lysosphingolipids) and molecules containing the glycerol backbone (lysoglycerophospholipids). The lysolipid structure renders these lipids more hydrophilic and versatile than their corresponding phospholipids.

Investigators at Yale University (New Haven, CT, USA) had shown previously that patients with Gaucher's disease, an inherited lipid storage disorder, had a significantly increased risk for developing myeloma.

In the February 11, 2016, issue of the New England Journal of Medicine, these investigators reported that gammopathy (a precursor to myeloma) in both mice and patients with Gaucher's disease was initiated by specific lipids, such as lyso-glucosylceramide (LGL1), and that the antibodies made by tumor cells in nearly a third of myeloma patients were directed against such lipids.

“Understanding the origin of any cancer has several implications for how to best prevent it,” said senior author Dr. Madhav Dhodapkar, professor of medicine and immunobiology at Yale University. “These studies set the stage for newer approaches to lower the levels of these lipids in patients with Gaucher's disease and others with precursors for myeloma. Potentially, this could be achieved with drugs or lifestyle changes to reduce the levels of lipids to lower the risk of cancer.”

Related Links:

Yale University



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.